Financial reports
20-F
2023 FY
Annual report (foreign)
10 May 24
NT 20-F
Notice of late annual filing (foreign)
1 May 24
20-F
2022 FY
Annual report (foreign)
28 Apr 23
20-F/A
2021 FY
Annual report (foreign) (amended)
26 Jan 23
20-F
2021 FY
Annual report (foreign)
3 May 22
NT 20-F
Notice of late annual filing (foreign)
3 May 22
Current reports
6-K
Current report (foreign)
17 May 24
6-K
Condensed Interim Consolidated Financial Statements
16 May 24
6-K
Current report (foreign)
30 Apr 24
6-K
XORTX Announces Publication of Key Research in ADPKD
22 Apr 24
6-K
XORTX Welcomes New Member to the Board of Directors
8 Apr 24
6-K
XORTX Announces Participation in Spring 2024 Investor Conferences
8 Apr 24
6-K
XORTX Announces New Clinical Advisory Board Member
27 Mar 24
6-K
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
19 Mar 24
6-K
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
3 Jan 24
6-K
XORTX Welcomes New Member to the Board of Directors
2 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Nov 23
424B3
Prospectus supplement
25 Aug 23
424B3
Prospectus supplement
25 Aug 23
424B3
Prospectus supplement
14 Aug 23
424B3
Prospectus supplement
14 Aug 23
POS AM
Prospectus update (post-effective amendment)
4 Aug 23
POS AM
Prospectus update (post-effective amendment)
4 Aug 23
F-3
Shelf registration (foreign)
27 Jan 23
424B3
Prospectus supplement
14 Nov 22
S-8
Registration of securities for employees
27 Oct 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
8 Aug 23
EFFECT
Notice of effectiveness
8 Aug 23
EFFECT
Notice of effectiveness
6 Feb 23
CORRESP
Correspondence with SEC
1 Feb 23
UPLOAD
Letter from SEC
31 Jan 23
EFFECT
Notice of effectiveness
3 Oct 22
EFFECT
Notice of effectiveness
23 Sep 22
CORRESP
Correspondence with SEC
22 Sep 22
CORRESP
Correspondence with SEC
22 Sep 22
CORRESP
Correspondence with SEC
21 Sep 22